World-first gene therapy for inherited blood disorders approved in UK

The treatment is the first to be licensed using the gene-editing tool known as Crispr, for which its inventors were awarded the Nobel prize in 2020.
The regulator has authorised the treatment for patients aged 12 and over (Peter Byrne/PA)
PA Wire
Jane Kirby16 November 2023

The UK’s medicines regulator has authorised a world-first gene therapy as a potential cure for two inherited blood disorders.

The treatment, Casgevy, for sickle cell disease and beta thalassemia, is the first to be licensed using the gene-editing tool known as Crispr, for which its inventors were awarded the Nobel prize in 2020.

The Medicines and Healthcare products Regulatory Agency (MHRA) said the treatment was for patients aged 12 and over “after a rigorous assessment of its safety, quality and effectiveness”.

Both sickle cell disease and beta thalassemia are genetic conditions caused by errors in the genes for haemoglobin, which is used by red blood cells to carry oxygen around the body.

Sickle cell disease is particularly common in people with an African or Caribbean family background, while beta thalassemia mainly affects people of Mediterranean, south Asian, south-east Asian and Middle Eastern origin.

Symptoms of sickle cell disease can include very severe pain, serious and life-threatening infections, and anaemia.

People with beta thalassemia can have severe anaemia. Patients often need a blood transfusion every three to five weeks, alongside regular injections and medicines.

Casgevy is designed to work by editing the faulty gene in a patient’s bone marrow stem cells so that the body produces functioning haemoglobin.

To date, a bone marrow transplant – which must come from a closely matched donor and carries a risk of rejection – has been the only permanent treatment option

Julian Beach, MHRA

For this to work, stem cells are taken out of bone marrow, edited in the lab and then infused back into the patient, with the potential to cure people.

The MHRA said clinical trials had found Casgevy restored healthy haemoglobin production in the majority of people.

In the clinical trial for sickle cell disease, 28 out of 29 patients in an analysis (97%) were free of severe pain for at least 12 months after treatment.

In the clinical trial for beta thalassemia, 39 out of 42 patients analysed (93%) did not need a red blood cell transfusion for at least 12 months after treatment.

The remaining three had more than a 70% reduction in the need for red cell transfusions.

There are limited medicines currently available to patients, so I welcome today’s news that a new treatment has been judged safe and effective, which has the potential to significantly improve the quality of life for so many

John James, chief executive of the Sickle Cell Society

Julian Beach, interim executive director of healthcare quality and access at the MHRA, said both conditions “are painful, life-long conditions that in some cases can be fatal”.

He added: “To date, a bone marrow transplant – which must come from a closely matched donor and carries a risk of rejection – has been the only permanent treatment option.”

John James, chief executive of the Sickle Cell Society, said: “Sickle cell disorder is an incredibly debilitating condition, causing significant pain for the people who live with it and potentially leading to early mortality.

“There are limited medicines currently available to patients, so I welcome today’s news that a new treatment has been judged safe and effective, which has the potential to significantly improve the quality of life for so many.”

The treatment has not yet been examined for more widespread use on the NHS.

We’re delighted this world-first therapy has been granted an MHRA licence, which brings us a step closer to it being available to people with severe sickle cell disease in the UK

Yasmin Sheikh, Anthony Nolan charity

Reshma Kewalramani, president of Vertex, which launched the drug together with Crispr Therapeutics, said: “Today is a historic day in science and medicine: this authorisation of Casgevy in Great Britain is the first regulatory authorisation of a Crispr-based therapy in the world.”

Yasmin Sheikh, head of policy and public affairs at Anthony Nolan, said: “We’re delighted this world-first therapy has been granted an MHRA licence, which brings us a step closer to it being available to people with severe sickle cell disease in the UK.

“Patients won’t be able to access Casgevy on the NHS until it is approved by Nice.

“We hope that Nice will listen to patients with severe sickle cell disease who desperately need better treatment options and make this innovative therapy available as quickly as possible.”

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in